STOCK TITAN

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Adial Pharmaceuticals (NASDAQ: ADIL) has announced its participation in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. CEO Cary Claiborne will deliver a presentation at 8:30 a.m. ET, and management will conduct one-on-one investor meetings throughout the day. The conference brings together institutional investors, corporate clients, and industry professionals to showcase innovations and financial strategies. Investors can register to attend and schedule meetings, with the presentation available via live stream.

Adial Pharmaceuticals (NASDAQ: ADIL) ha annunciato la sua partecipazione alla ThinkEquity Conference il 30 ottobre 2024, presso il Mandarin Oriental Hotel di New York. Il CEO Cary Claiborne farà una presentazione alle 8:30 a.m. ET, e il management condurrà incontri individuali con gli investitori durante tutto il giorno. La conferenza riunisce investitori istituzionali, clienti aziendali e professionisti del settore per mostrare innovazioni e strategie finanziarie. Gli investitori possono registrarsi per partecipare e pianificare incontri, con la presentazione disponibile tramite streaming live.

Adial Pharmaceuticals (NASDAQ: ADIL) ha anunciado su participación en la ThinkEquity Conference el 30 de octubre de 2024, en el Mandarin Oriental Hotel de Nueva York. El CEO Cary Claiborne realizará una presentación a las 8:30 a.m. ET, y la dirección llevará a cabo reuniones individuales con los inversores a lo largo del día. La conferencia reúne a inversores institucionales, clientes corporativos y profesionales de la industria para mostrar innovaciones y estrategias financieras. Los inversores pueden registrarse para asistir y programar reuniones, con la presentación disponible a través de transmisión en vivo.

Adial Pharmaceuticals (NASDAQ: ADIL)는 2024년 10월 30일 뉴욕의 만다린 오리엔탈 호텔에서 열리는 ThinkEquity Conference에 참여할 것이라고 발표했습니다. CEO Cary Claiborne는 오전 8시 30분 ET에 발표를 할 예정이며, 경영진은 하루 종일 투자자와 일대일 회의를 진행합니다. 이 회의는 기관 투자자, 기업 고객 및 업계 전문가를 한자리에 모아 혁신과 금융 전략을 선보입니다. 투자자는 참석 등록을 하고 회의를 예약할 수 있으며, 발표는 라이브 스트리밍을 통해 제공됩니다.

Adial Pharmaceuticals (NASDAQ: ADIL) a annoncé sa participation à la ThinkEquity Conference le 30 octobre 2024, à l'hôtel Mandarin Oriental de New York. Le PDG Cary Claiborne fera une présentation à 8h30 ET, et la direction organisera des réunions individuelles avec les investisseurs tout au long de la journée. La conférence rassemble des investisseurs institutionnels, des clients d'entreprises et des professionnels de l'industrie pour présenter des innovations et des stratégies financières. Les investisseurs peuvent s'inscrire pour assister et planifier des réunions, la présentation étant disponible en diffusion en direct.

Adial Pharmaceuticals (NASDAQ: ADIL) hat seine Teilnahme an der ThinkEquity Conference am 30. Oktober 2024 im Mandarin Oriental Hotel in New York angekündigt. CEO Cary Claiborne wird um 8:30 Uhr ET eine Präsentation halten, und das Management wird den ganzen Tag über Einzelgespräche mit Investoren führen. Die Konferenz bringt institutionelle Investoren, Unternehmensklienten und Branchenfachleute zusammen, um Innovationen und Finanzstrategien vorzustellen. Investoren können sich registrieren, um teilzunehmen und Meetings zu planen, während die Präsentation per Live-Stream verfügbar ist.

Positive
  • None.
Negative
  • None.

GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies.

Cary Claiborne, Chief Executive Officer of Adial, will be presenting at 8:30 a.m. ET on October 30th. Management will also be holding one-on-one investor meetings throughout the day. Interested investors can register to attend and schedule on-on-one meetings here.

The presentation will also be live-streamed at the following link: https://wsw.com/webcast/tep25/adil/1651104.

About ThinkEquity

ThinkEquity is a boutique investment bank founded by professionals who have collaborated for over a decade, collectively financing over $50 billion in public and private capital raises, restructurings, and mergers and acquisitions. Past ThinkEquity conferences have featured over 70 company presentations, 700+ attendees, and 500+ one-on-one meetings, providing a valuable platform for companies and investors to connect. To register to attend The ThinkEquity Conference, please follow this link.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.

If you are interested in exploring partnership opportunities with Adial, we invite you to reach out to us (BD@adialpharma.com) to discuss how our joint efforts can bring about positive change in the millions of patients who are struggling with addiction.

Forward-Looking Statements

This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding advancing AD04 and delivering innovative, genetically-targeted treatments for addiction, harnessing cutting-edge science for the betterment of countless lives affected by addiction, paving the way for treatments that are more effective and have fewer side effects by understanding the genetic factors that play a role in addiction and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: ADIL@crescendo-ir.com


FAQ

When is Adial Pharmaceuticals (ADIL) presenting at the 2024 ThinkEquity Conference?

Adial Pharmaceuticals will present at 8:30 a.m. ET on October 30, 2024, at the Mandarin Oriental Hotel in New York.

Where can investors watch Adial Pharmaceuticals' (ADIL) ThinkEquity Conference presentation?

Investors can watch the live stream of the presentation at https://wsw.com/webcast/tep25/adil/1651104.

What type of meetings will Adial Pharmaceuticals (ADIL) conduct at the 2024 ThinkEquity Conference?

Adial's management will be conducting one-on-one investor meetings throughout the day of the conference.

What is the purpose of the ThinkEquity Conference where Adial (ADIL) is presenting?

The ThinkEquity Conference gathers institutional investors, corporate clients, and industry professionals to highlight groundbreaking innovations and financial strategies.

Adial Pharmaceuticals, Inc

NASDAQ:ADIL

ADIL Rankings

ADIL Latest News

ADIL Stock Data

6.42M
6.41M
1.8%
4.43%
0.8%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHARLOTTESVILLE